1 Intravenous bolus doses of thyrotrophin releasing hormone (TRH, 50-1000 mu g) caused statistically significant, non-dose dependent and transient rises in blood pressure, heart rate and plasma catecholamines in healthy young males. 2 Mean peak incremental rises in systolic blood pressure (mean +/- s.e. mean) following 50, 200 and 500 mu g TRH were 14.3 +/- 2.9 mmHg, 15.7 +/- 3.2 mmHg and 17.1 +/- 3.9 mmHg respectively (all P < 0.05 vs placebo). Mean incremental rises in heart rate for the three doses of TRH were 8.2 +/- 2.2 beats min(-1), 7.1 +/- 1.8 beats min(-1), and 10.7 +/- 2.9 beats min(-1) respectively (all P < 0.05 vs placebo). 3 Following the 50 mu g and 1000 mu g doses of TRH, plasma noradrenaline and adrenaline rose significantly (P < 0.05) between 4 and 8 min. Mean +/- s.e. mean incremental plasma noradrenaline rise following 50, 200 and 1000 mu g TRH were 0.4 +/- 0.13 nmol l(-1), 0.37 +/- 0.21 nmol l(-1) and 0.41 +/- 0.18 nmol l(-1) respectively. Mean +/- s.e. mean incremental rise in adrenaline for the 50, 200 and 1000 mu g dose were 0.13 +/- 0.04 nmol l(-1), 0.08 +/- 0.03 nmol l(-1), and 0.11 +/- 0.05 nmol l(-1) respectively. 4 Following administration of the ganglion blocking drug pentolinium (5 mg) the incremental systolic blood pressure and heart rate rises following 500 mu g TRH alone 16.6 +/- 2.8 mmHg and 10.4 +/- 3.1 beats min(-1) respectively. 5 The rises in plasma noradrenaline and adrenaline following TRH were attenuated by prior ganglion blockade. 6 alpha-adrenoceptor blockade with thymoxamine (0.3 mg kg(-1) bolus + 0.3 mg kg(-1) h(-1) infusion), singly and combined with intravenous propranolol (10 mg i.v. over 10 min), did not alter the presser or tachycardic effects of 500 mu g TRH. 7 In conclusion, although plasma noradrenaline rises following i.v. TRH, suggesting activation of the sympathetic nervous system, this effect is not responsible for the presser response to TRH, which appears to be due to either a direct vasoconstrictive effect on the peripheral resistance vessels or a direct inotropic/chronotropic effect on the heart.

The acute cardiovascular actions of intravenous thyrotrophin releasing hormone (TRH) in man are mediated by non-catecholaminergic mechanisms

Corsello S;
1996-01-01

Abstract

1 Intravenous bolus doses of thyrotrophin releasing hormone (TRH, 50-1000 mu g) caused statistically significant, non-dose dependent and transient rises in blood pressure, heart rate and plasma catecholamines in healthy young males. 2 Mean peak incremental rises in systolic blood pressure (mean +/- s.e. mean) following 50, 200 and 500 mu g TRH were 14.3 +/- 2.9 mmHg, 15.7 +/- 3.2 mmHg and 17.1 +/- 3.9 mmHg respectively (all P < 0.05 vs placebo). Mean incremental rises in heart rate for the three doses of TRH were 8.2 +/- 2.2 beats min(-1), 7.1 +/- 1.8 beats min(-1), and 10.7 +/- 2.9 beats min(-1) respectively (all P < 0.05 vs placebo). 3 Following the 50 mu g and 1000 mu g doses of TRH, plasma noradrenaline and adrenaline rose significantly (P < 0.05) between 4 and 8 min. Mean +/- s.e. mean incremental plasma noradrenaline rise following 50, 200 and 1000 mu g TRH were 0.4 +/- 0.13 nmol l(-1), 0.37 +/- 0.21 nmol l(-1) and 0.41 +/- 0.18 nmol l(-1) respectively. Mean +/- s.e. mean incremental rise in adrenaline for the 50, 200 and 1000 mu g dose were 0.13 +/- 0.04 nmol l(-1), 0.08 +/- 0.03 nmol l(-1), and 0.11 +/- 0.05 nmol l(-1) respectively. 4 Following administration of the ganglion blocking drug pentolinium (5 mg) the incremental systolic blood pressure and heart rate rises following 500 mu g TRH alone 16.6 +/- 2.8 mmHg and 10.4 +/- 3.1 beats min(-1) respectively. 5 The rises in plasma noradrenaline and adrenaline following TRH were attenuated by prior ganglion blockade. 6 alpha-adrenoceptor blockade with thymoxamine (0.3 mg kg(-1) bolus + 0.3 mg kg(-1) h(-1) infusion), singly and combined with intravenous propranolol (10 mg i.v. over 10 min), did not alter the presser or tachycardic effects of 500 mu g TRH. 7 In conclusion, although plasma noradrenaline rises following i.v. TRH, suggesting activation of the sympathetic nervous system, this effect is not responsible for the presser response to TRH, which appears to be due to either a direct vasoconstrictive effect on the peripheral resistance vessels or a direct inotropic/chronotropic effect on the heart.
1996
TRH
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14245/881
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
social impact